Vemurafenib (Zelboraf) for the indication ‘BRAF V600 mutation-positive unresectable or metastatic melanoma’

Vemurafenib has an added therapeutic value in comparison with decarbazine for the treatment of adult patients in a relatively good clinical condition (ECOG 0/1) with a BRAF V600 mutation-positive unresectable or metastatic melanoma.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.